BioMimetic Therapeutics

About:

BioMimetic Therapeutics is a provider of orthopedic consultation and health care to patients.

Top Investors: Novo Holdings, Noro-Moseley Partners, InterWest Partners, CMEA Ventures, MB Venture Partners

Description:

BioMimetic Therapeutics is a biotechnology company that develops products to help stimulate the body natural tissue regenerative process. The company's products and product candidates include Augment Injectable and Augment Rotator Cuff for several orthopedic and sports medicine indications comprising the treatment of foot and ankle fusions, the stimulation of wrist fracture healing, and the surgical treatment of rotator cuff tears, as well as Augment Tendinopathy Injection for injuries cause of tendon overuse. BioMimetic Therapeutics was founded on 1999 and is headquartered in Franklin, Tennessee.

Total Funding Amount:

$59.9M

Headquarters Location:

Franklin, Tennessee, United States

Founded Date:

1999-01-01

Founders:

Samuel E. Lynch

Number of Employees:

51-100

Last Funding Date:

2009-06-25

IPO Status:

Delisted

Industries: